Cynata Therapeutics Limited ( (AU:CYP) ) has provided an announcement.
Cynata Therapeutics Limited has announced a change in the director’s interest notice, specifically regarding Dr. Geoffrey Brooke. The change involved the expiry of 69,767 listed options exercisable at $0.30, which expired on April 1, 2025. This adjustment reflects a routine update in the director’s securities holdings, with implications for the company’s governance and transparency practices.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited operates in the biotechnology industry, focusing on the development of stem cell therapies. The company is engaged in creating innovative treatments for various medical conditions using its proprietary Cymerus™ technology.
YTD Price Performance: -27.89%
Average Trading Volume: 2,205
Technical Sentiment Signal: Buy
Current Market Cap: $26.8M
For an in-depth examination of CYP stock, go to TipRanks’ Stock Analysis page.